Humacyte, Inc. Revenue
Humacyte, Inc. (HUMA) reported Revenue of $406.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-12
- Humacyte, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $406.00K, a 34.88% increase year-over-year.
- Humacyte, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $495.00K, a 4.26% decline year-over-year.
- Humacyte, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $467.00K.
- Humacyte, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $753.00K.
- Humacyte, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $2.04M.
- Humacyte, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $406.00K 10-Q · filed 2026-08-12 | $901.00K 10-Q · filed 2026-08-12 | $1.37M derived: sum of 3 quarters · filed 2026-08-12 | $2.12M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $495.00K 10-Q · filed 2026-05-13 | $962.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.72M derived: sum of 3 quarters · filed 2026-05-13 | $2.02M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $467.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.22M derived: sum of 2 quarters · filed 2026-03-27 | $1.52M derived: sum of 3 quarters · filed 2026-08-12 | $2.04M 10-K · filed 2026-03-27 |
| 2025-09-30 | $753.00K 10-Q · filed 2025-11-12 | $1.05M derived: sum of 2 quarters · filed 2026-08-12 | $1.57M 10-Q · filed 2025-11-12 | $1.57M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $301.00K 10-Q · filed 2026-08-12 | $818.00K 10-Q · filed 2026-08-12 | $818.00K derived: sum of 3 quarters · filed 2026-08-12 | $818.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $517.00K 10-Q · filed 2026-05-13 | $517.00K derived: sum of 2 quarters · filed 2026-05-13 | $517.00K derived: sum of 3 quarters · filed 2026-05-13 | $517.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 derived: sum of 2 quarters · filed 2026-03-27 | $0.00 derived: sum of 3 quarters · filed 2026-03-27 | $0.00 10-K · filed 2026-03-27 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |